←
Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI3,594 posts
Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI avatar

Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI

@ErwMulia

Interventional Cardiologist @ISIC_Official/ food and comedy enthusiast/ 3rd gen. Chinese-Indonesian🇲🇨/ FIHA,FAsCC,FAPSC,FESC,FAPSIC,FACC,FSCAI

◷ Joined May 2022▧ 142 Photos and videos
Journal of Cardiovascular Pharmacology avatar
⟳ Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI retweeted
Journal of Cardiovascular Pharmacology@JCVPOnline·Nov 17

Can we stop aspirin after just one month of DAPT following PCI without compromising ischaemic safety? An analysis of 11 randomized trials involving 37,443 patients found that P2Y12-inhibitor monotherapy substantially reduced bleeding, with broadly comparable ischaemic outcomes following one- versus three-month aspirin withdrawal. However, an early ischaemic signal with near-immediate withdrawal highlights the importance of timing. Does the future of post-PCI antiplatelet therapy lie in earlier aspirin withdrawal? Read the study and share your perspective! #Cardiology #CardioTwitter #PCI #AntiplateletTherapy #InterventionalCardiology pubmed.ncbi.nlm.nih.gov/4283… @drhbulluck

Post attachment
ISIC avatar
⟳ Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI retweeted
ISIC@ISIC_Official·Nov 17

🌍 ISICAM 2026: A World-Class Interventional Cardiology Event! A remarkable achievement and a new milestone for interventional cardiology in Indonesia! 🏆 2,111 Participants 📑 256 Abstract Submissions 🌏 67 International Faculty 🎓 39 Symposia 🤝 5 Joint Sessions 🔬 8 Workshops for Interventional Cardiologists 🩺 4 Workshops for Nurses & Allied Health Professionals ❤️ 18 Live Cases from 4 overseas centers across 4 countries The 18th ISICAM 2026 brought together leading experts, international faculty, researchers, and healthcare professionals under the theme: “Translating Evidence into Practice in Cardiovascular Intervention.” Three days of scientific excellence, knowledge sharing, hands-on learning, international collaboration, and inspiring discussions. Thank you to all faculty members, participants, abstract presenters, partners, and the organizing committee for making ISICAM 2026 an outstanding success! ISICAM — Raising the Standard of Interventional Cardiology in Indonesia and Beyond! 🚀 #ISICAM2026 #WorldClassCardiology #InterventionalCardiology #CardiovascularInnovation #ScientificExcellence

Post attachmentPost attachmentPost attachmentPost attachment
Dr. Filippo Cademartiri avatar
⟳ Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI retweeted
Dr. Filippo Cademartiri@FCademartiri·Nov 17

BUYING A PHOTON-COUNTING CT SCANNER DOES NOT AUTOMATICALLY CREATE A PHOTON-COUNTING CT PRACTICE. It gives you the technology. NOT NECESSARILY THE EXPERTISE TO USE IT. A new review published in Cancer Imaging explores the clinical applications of Photon-Counting CT in abdominal oncology. Beyond the expected improvements in spatial resolution, contrast-to-noise ratio, and spectral imaging, the authors highlight something much more important. PCCT REQUIRES A DIFFERENT APPROACH TO CLINICAL IMAGING. Consider a few examples: ➤ 40 keV may improve pancreatic tumor conspicuity, but it is not necessarily optimal for detecting liver lesions. ➤ In renal imaging, low-keV reconstructions may increase pseudoenhancement and lead to incorrect lesion characterization. ➤ Ultra-high spatial resolution is not always the best choice for quantitative imaging. ➤ Better image quality does not automatically translate into better diagnostic accuracy or clinical outcomes. MY TAKE Photon-Counting CT is not simply conventional CT with a better detector. It is a different imaging technology, with capabilities that require specific knowledge, protocols, reconstruction strategies, and interpretation skills. And this has important consequences. YOU CANNOT JUST COPY YOUR OLD CT PROTOCOLS, PRESS START, AND EXPECT A REVOLUTION. You need dedicated training. You need experienced radiologists and technologists. You need protocol optimization, quality control, and continuous clinical evaluation. And above all, you need to understand WHY, WHEN, AND HOW to exploit the technology for each patient. The scanner is only the starting point. THE REAL UPGRADE IS NOT JUST THE HARDWARE. IT IS THE KNOWLEDGE BEHIND IT. Jadav V et al. Clinical applications of photon-counting CT in abdominal oncologic imaging: a primer for developing a clinical practice. Cancer Imaging. 2026;26:159. DOI: 10.1186/s40644-026-01107-8. #PhotonCountingCT #PCCT #Radiology #MedicalImaging #OncologicImaging #RadiologyEducation #ClinicalInnovation PS: the exact same is true for Cardiovascular Imaging. If you think you get a PCCT and then you exploit the advantages by approaching it as the previous EiD CT scanner you are on the wrong track and you will lose time, money and opportunity. Research, education, and a complete change of approach are mandatory.

Post attachment
JACC Journals avatar
⟳ Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI retweeted
JACC Journals@JACCJournals·Nov 14

#JACCCEP study: In persistent #AFib, baseline LA volume index did not predict arrhythmia recurrence after first-time ablation but was associated with higher AFib burden and persistent recurrence phenotype at 1-year postablation. bit.ly/4iTpFb2 #epAblation

Post attachment
Victor Dayan avatar
⟳ Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI retweeted
Victor Dayan@VictorDayan1·Nov 14

1/8 🧵 Can PCI be declared non-inferior to CABG while offering no benefit—or potentially worse outcomes—than optimal medical therapy? YES. This is one of the most overlooked methodological problems in coronary revascularization trials. Here’s why. 👇

Post attachment
summitmd_cvrf avatar
⟳ Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI retweeted
summitmd_cvrf@summitmd_cvrf·Nov 10

TCTAP is heading to 🇮🇩Jakarta for #ISICAM2026! Be sure to stop by our booth, and don't miss the joint session on Left Main PCI, where experts from Korea and Indonesia will share their perspectives on key challenges in complex coronary interventions. See you soon! 👋#TCTAP2027

Post attachmentPost attachment
Neil Floch MD avatar
⟳ Erwin Mulia, FIHA,FESC,FACC,FAPSIC,FSCAI retweeted
Neil Floch MD@NeilFlochMD·Nov 10

Once you start, you should not stop GLP-1

Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study. Find out more in @LancetRH_Europe: spkl.io/60137wUtS

Post attachment